Form 4: Palatin Technologies Director Hull Receives Stock Options and Restricted Share Units

Director Joseph Stanley Hull of Palatin Technologies receives stock options and restricted share units following certification related to the company's 2011 Stock Incentive Plan.

Summary

• On July 15, 2024, Joseph Stanley Hull, a director of Palatin Technologies, acquired 12,000 shares of common stock and stock options for 17,000 shares.
• These acquisitions were grants of restricted share units and stock options under the 2011 Stock Incentive Plan.
• The restricted share units vest on June 4, 2025, and each represents the right to receive one share of common stock without further payment.
• The stock options have an exercise price of $1.83 and also vest on June 4, 2025, prorated monthly if the director doesn't serve until June 30, 2025.
• The grants were subject to certification by the Chief Financial Officer regarding shareholder approval and absence of impediments, which occurred on July 15, 2024.
• Following these transactions, Hull directly owns 42,272 shares of common stock and holds options for 57,780 shares.

Sentiment

Score: 7

Explanation: The document reflects a routine equity grant, which is generally viewed positively as it aligns management interests with shareholders. There are no indications of negative news or concerns.

Positives

• The grant of stock options and restricted share units to a director aligns their interests with those of the shareholders.
• The vesting schedules incentivize continued service and contribution to the company.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting and expiration dates of the granted securities.

Industry Context

This type of equity grant is a common practice in the pharmaceutical industry to incentivize and retain key personnel, aligning their interests with the long-term success of the company.

Comparison to Industry Standards

• Stock option and restricted share unit grants are standard compensation practices in the biotechnology and pharmaceutical industries.
• Companies like Amgen, Gilead Sciences, and Biogen routinely use similar equity-based compensation to attract and retain talent.
• The vesting schedules and exercise prices are generally aligned with industry norms, aiming to incentivize long-term performance and shareholder value creation.

Stakeholder Impact

• Shareholders may view the equity grant positively as it incentivizes the director to work towards increasing shareholder value.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates